Last reviewed · How we verify
Brolucizumab Injection [Beovu]
Brolucizumab is a single-chain antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) to reduce abnormal blood vessel growth and leakage in the retina.
Brolucizumab is a single-chain antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) to reduce abnormal blood vessel growth and leakage in the retina. Used for Wet age-related macular degeneration (AMD), Diabetic macular edema (DME).
At a glance
| Generic name | Brolucizumab Injection [Beovu] |
|---|---|
| Sponsor | Yeungnam University College of Medicine |
| Drug class | Anti-VEGF monoclonal antibody fragment |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Brolucizumab binds to VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF-A signaling, it reduces fluid accumulation and abnormal vessel formation in conditions like wet age-related macular degeneration and diabetic macular edema. As a smaller antibody fragment compared to full monoclonal antibodies, it may offer improved retinal penetration.
Approved indications
- Wet age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular inflammation
- Retinal detachment
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: